← back to search

Dan Wu

Nanjing Drum Tower Hospital · CN
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Gastric Cancer Management and Outcomes, Ferroptosis and cancer prognosis, and Lung Cancer Treatments and Mutations.
h-index
21
citations
1,675
works
76
NIH funding
primary concept
Medicine
email

Recent publications

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial
The Lancet Oncology 2025cited by 44position: middledoi
A Potential Approach of Mesenchymal Stem Cells Combined Silybin for Synergistic Treatment in Rheumatoid Arthritis via ICOS/ICOSL
MedComm 2025cited by 0position: middledoi
Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05)
Journal of Clinical Oncology 2024cited by 42position: middledoi
Development and Validation of a Modified Khorana Score for Predicting Venous Thromboembolism in Newly Diagnosed Stage IV Lung Cancer
Angiology 2023cited by 5position: lastdoi
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
BMC Medicine 2022cited by 62position: middledoi
Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer
JAMA Network Open 2022cited by 31position: middledoi
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
The Lancet Oncology 2021cited by 431position: middledoi
Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer
Medicine 2021cited by 40position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Dong Shen · Yancheng Second People's Hospital1 papers (2021–2021)Shusen Chen · University of California System1 papers (2021–2021)Mingjuan Jin · Zhejiang University1 papers (2022–2022) · 1 papers (2022–2022) · 1 papers (2025–2025) · 1 papers (2022–2022)Xinbao Wang · Capital University1 papers (2022–2022)Jianfei Fu · Sun Yat-sen University Cancer Center1 papers (2022–2022)Congying Xie · Sun Yat-sen University Cancer Center1 papers (2022–2022)Xiaoyu Wu · First People's Hospital of Chongqing1 papers (2022–2022)Nanyao Wang · Nantong University1 papers (2023–2023)Shenpeng Ying · Taizhou Central Hospital1 papers (2022–2022)Jiren Yu · Hangzhou First People's Hospital1 papers (2022–2022)Zhicheng Zhao · Shandong University of Technology1 papers (2022–2022)Xiaoping Huang · Ningbo University1 papers (2022–2022)Xiaosun Liu · Zhejiang University1 papers (2022–2022)Dongqing Lv · East China University of Political Science and Law1 papers (2022–2022)Baixia Yang · Nantong University1 papers (2021–2021)Zhengbo Song · Institute of Hematology & Blood Diseases Hospital1 papers (2022–2022)Zekuan Xu · Xuzhou Medical College1 papers (2022–2022)